Athira Pharma, INC. 8-K/A Filing
Ticker: LONA · Form: 8-K/A · Filed: Dec 18, 2025 · CIK: 1620463
Sentiment: neutral
Filing Stats: 4,681 words · 19 min read · ~16 pages · Grade level 18.6 · Accepted 2025-12-18 08:24:52
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ATHA The Nasdaq
- $6.35 — s and PIPE Series B Common Warrants) is $6.35 and the purchase price for each PIPE Pr
- $6.349 — s and PIPE Series B Common Warrants) is $6.349 per each underlying PIPE Pre-Funded War
- $90 m — cement are expected to be approximately $90 million, excluding placement agent fees a
- $0.001 — be exercisable at an exercise price of $0.001 per share, subject to customary adjustm
- $7.62 — Warrants will have an exercise price of $7.62 per share payable on a cashless net exe
- $20.0 million — have agreed to purchase an aggregate of $20.0 million of the PIPE Securities. Joseph Edelman,
- $34.9 million — mpany will issue Sermonix approximately $34.9 million in equity pursuant to a securities purc
- $16.8 m — vice providers that total approximately $16.8 million, and make payments to Sermonix of
- $75,000 — llion, and make payments to Sermonix of $75,000 per month, subject to adjustment from t
- $100.0 m — onix up to a maximum aggregate total of $100.0 million, a portion of which may be payabl
- $10.5 million — gand up to a maximum aggregate total of $10.5 million in regulatory milestones and $10.5 mill
Filing Documents
- atha-20251218.htm (8-K/A) — 431KB
- atha-ex4_1.htm (EX-4.1) — 208KB
- atha-ex4_2.htm (EX-4.2) — 244KB
- atha-ex4_3.htm (EX-4.3) — 227KB
- atha-ex4_4.htm (EX-4.4) — 200KB
- atha-ex4_5.htm (EX-4.5) — 244KB
- atha-ex4_6.htm (EX-4.6) — 239KB
- atha-ex10_1.htm (EX-10.1) — 556KB
- atha-ex10_2.htm (EX-10.2) — 344KB
- atha-ex99_1.htm (EX-99.1) — 54KB
- atha-ex99_2.htm (EX-99.2) — 57KB
- atha-ex99_3.htm (EX-99.3) — 708KB
- img194740669_0.jpg (GRAPHIC) — 34KB
- img194740669_1.jpg (GRAPHIC) — 64KB
- img194740669_2.jpg (GRAPHIC) — 32KB
- img194740669_3.jpg (GRAPHIC) — 70KB
- img194740669_4.jpg (GRAPHIC) — 138KB
- img194740669_5.jpg (GRAPHIC) — 71KB
- img194740669_6.jpg (GRAPHIC) — 89KB
- img194740669_7.jpg (GRAPHIC) — 69KB
- img194740669_8.jpg (GRAPHIC) — 33KB
- img194740669_9.jpg (GRAPHIC) — 94KB
- img194740669_10.jpg (GRAPHIC) — 70KB
- img194740669_11.jpg (GRAPHIC) — 35KB
- img194740669_12.jpg (GRAPHIC) — 63KB
- atha-ex99_2s1.jpg (GRAPHIC) — 198KB
- atha-ex99_2s2.jpg (GRAPHIC) — 912KB
- atha-ex99_2s3.jpg (GRAPHIC) — 214KB
- atha-ex99_2s4.jpg (GRAPHIC) — 357KB
- atha-ex99_2s5.jpg (GRAPHIC) — 183KB
- atha-ex99_2s6.jpg (GRAPHIC) — 368KB
- atha-ex99_2s7.jpg (GRAPHIC) — 193KB
- atha-ex99_2s8.jpg (GRAPHIC) — 415KB
- atha-ex99_2s9.jpg (GRAPHIC) — 426KB
- atha-ex99_2s10.jpg (GRAPHIC) — 388KB
- atha-ex99_2s11.jpg (GRAPHIC) — 398KB
- atha-ex99_2s12.jpg (GRAPHIC) — 383KB
- atha-ex99_2s13.jpg (GRAPHIC) — 413KB
- atha-ex99_2s14.jpg (GRAPHIC) — 422KB
- atha-ex99_2s15.jpg (GRAPHIC) — 406KB
- atha-ex99_2s16.jpg (GRAPHIC) — 423KB
- atha-ex99_2s17.jpg (GRAPHIC) — 429KB
- atha-ex99_2s18.jpg (GRAPHIC) — 287KB
- atha-ex99_2s19.jpg (GRAPHIC) — 389KB
- atha-ex99_2s20.jpg (GRAPHIC) — 353KB
- atha-ex99_2s21.jpg (GRAPHIC) — 441KB
- atha-ex99_2s22.jpg (GRAPHIC) — 478KB
- atha-ex99_2s23.jpg (GRAPHIC) — 419KB
- atha-ex99_2s24.jpg (GRAPHIC) — 429KB
- atha-ex99_2s25.jpg (GRAPHIC) — 433KB
- atha-ex99_2s26.jpg (GRAPHIC) — 401KB
- atha-ex99_2s27.jpg (GRAPHIC) — 271KB
- atha-ex99_2s28.jpg (GRAPHIC) — 177KB
- atha-ex99_2s29.jpg (GRAPHIC) — 430KB
- atha-ex99_2s30.jpg (GRAPHIC) — 349KB
- atha-ex99_2s31.jpg (GRAPHIC) — 398KB
- atha-ex99_2s32.jpg (GRAPHIC) — 284KB
- atha-ex99_2s33.jpg (GRAPHIC) — 412KB
- atha-ex99_2s34.jpg (GRAPHIC) — 374KB
- atha-ex99_2s35.jpg (GRAPHIC) — 380KB
- atha-ex99_2s36.jpg (GRAPHIC) — 441KB
- atha-ex99_2s37.jpg (GRAPHIC) — 239KB
- atha-ex99_2s38.jpg (GRAPHIC) — 238KB
- atha-ex99_2s39.jpg (GRAPHIC) — 214KB
- atha-ex99_2s40.jpg (GRAPHIC) — 231KB
- atha-ex99_2s41.jpg (GRAPHIC) — 183KB
- atha-ex99_2s42.jpg (GRAPHIC) — 181KB
- 0001193125-25-323786.txt ( ) — 27118KB
- atha-20251218.xsd (EX-101.SCH) — 27KB
- atha-20251218_htm.xml (XML) — 5KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. Private Placement Financing On December 18, 2025, Athira Pharma, Inc. (the " Company " or " Athira ") entered into a securities purchase agreement (the " PIPE Securities Purchase Agreement ") with a select group of investors, including Commodore Capital LP (" Commodore "), TCG Crossover Management LLC (" TGCX "), Perceptive Advisors (" Perceptive ") and other accredited investors, one of which is affiliated with a member of the board of directors (the " Board ") of the Company (collectively, the " PIPE Purchasers "), pursuant to which the PIPE Purchasers have agreed to purchase and the Company has agreed to issue and sell, by way of a private placement (the " Private Placement ") an aggregate of (a) 5,356,547 shares (the " PIPE Initial Shares ") of the Company's common stock, par value $0.0001 per share (the " Common Stock ") and (b) pre-funded warrants (the " PIPE Pre-Funded Warrants ") to purchase 8,816,684 shares of Common Stock (the " PIPE Pre-Funded Warrant Shares ") and (c) accompanying warrants (the " PIPE Series A Common Warrants ") to purchase 23,031,494 shares of Common Stock and/or shares underlying pre-funded warrants, representing 162.5% of the aggregate of PIPE Initial Shares and the shares of Common Stock underlying the PIPE Pre-Funded Warrants (the shares, or the shares issuable pursuant to such pre-funded warrants, the " PIPE Series A Common Warrant Shares ") and (d) accompanying warrants (the " PIPE Series B Common Warrants " and, together with the PIPE Series A Common Warrants and the PIPE Pre-Funded Warrants, the " PIPE Warrants ", and the PIPE Warrants, together with the PIPE Initial Shares, the " PIPE Securities ") to purchase 21,259,842 shares of Common Stock and/or shares underlying pre-funded warrants, representing 150% of the aggregate of PIPE Initial Shares and the shares of Common Stock underlying the PIPE Pre-Funded Warrants (the shares, or the shares issuable pursuant to such pre